These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38680895)

  • 1. Prognosis value of galectin-3 in patients with dilated cardiomyopathy: a meta-analysis.
    Xiong Y; Zhang Q
    PeerJ; 2024; 12():e17201. PubMed ID: 38680895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.
    Hu DJ; Xu J; Du W; Zhang JX; Zhong M; Zhou YN
    Int J Cardiovasc Imaging; 2016 Dec; 32(12):1725-1733. PubMed ID: 27566192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy.
    Vergaro G; Del Franco A; Giannoni A; Prontera C; Ripoli A; Barison A; Masci PG; Aquaro GD; Cohen Solal A; Padeletti L; Passino C; Emdin M
    Int J Cardiol; 2015 Apr; 184():96-100. PubMed ID: 25697876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients.
    Wojciechowska C; Romuk E; Nowalany-Kozielska E; Jacheć W
    Hellenic J Cardiol; 2017; 58(5):350-359. PubMed ID: 28363768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy.
    Raafs AG; Verdonschot JAJ; Henkens MTHM; Adriaans BP; Wang P; Derks K; Abdul Hamid MA; Knackstedt C; van Empel VPM; Díez J; Brunner-La Rocca HP; Brunner HG; González A; Bekkers SCAM; Heymans SRB; Hazebroek MR
    Eur J Heart Fail; 2021 Jun; 23(6):933-944. PubMed ID: 33928704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognostic value of combined free triiodothyronine and late gadolinium enhancement in nonischemic dilated cardiomyopathy.
    Zhang K; Wang W; Zhao S; Katz SD; Iervasi G; Gerdes AM; Tang YD
    Clin Cardiol; 2018 Jan; 41(1):96-103. PubMed ID: 29360143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker.
    Besler C; Lang D; Urban D; Rommel KP; von Roeder M; Fengler K; Blazek S; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P
    Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28288987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of blood pressure response plus gadolinium enhancement in dilated cardiomyopathy.
    Tateishi E; Noguchi T; Goto Y; Morita Y; Ishibashi-Ueda H; Yamada N; Kanzaki H; Nishimura K; Miyamoto Y; Anzai T; Ogawa H; Yasuda S
    Heart; 2015 May; 101(10):774-80. PubMed ID: 25761994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of myocardial fibrosis detected by late gadolinium-enhanced MRI with clinical outcomes in patients with diabetes: a systematic review and meta-analysis.
    Yang Z; Xu R; Wang JR; Xu HY; Fu H; Xie LJ; Yang MX; Zhang L; Wen LY; Liu H; Li H; Yang ZG; Guo YK
    BMJ Open; 2022 Jan; 12(1):e055374. PubMed ID: 35017252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy.
    Latus H; Gummel K; Klingel K; Moysich A; Khalil M; Mazhari N; Bauer J; Kandolf R; Schranz D; Apitz C
    J Cardiovasc Magn Reson; 2015 May; 17(1):34. PubMed ID: 25976093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of late gadolinium enhancement in dilated cardiomyopathy patients. A meta-analysis.
    Shi HW; Pu P; Deng W; Zhou H; Bian ZY; Shen DF; Xie J; Salerno M; Tang QZ
    Saudi Med J; 2013 Jul; 34(7):719-26. PubMed ID: 23860892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of LGALS3 gene polymorphisms on susceptibility and prognosis of dilated cardiomyopathy in a Northern Han Chinese population.
    Zhang Y; Wang Y; Zhai M; Gan T; Zhao X; Zhang R; An T; Huang Y; Zhou Q; Zhang J
    Gene; 2018 Feb; 642():293-298. PubMed ID: 29129812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-3 deficiency ameliorates fibrosis and remodeling in dilated cardiomyopathy mice with enhanced Mst1 signaling.
    Nguyen MN; Ziemann M; Kiriazis H; Su Y; Thomas Z; Lu Q; Donner DG; Zhao WB; Rafehi H; Sadoshima J; McMullen JR; El-Osta A; Du XJ
    Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H45-H60. PubMed ID: 30387702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between late gadolinium enhancement and outcome in dilated cardiomyopathy: A meta-analysis.
    Feng XY; He WF; Zhang TY; Wang LL; Yang F; Feng YL; Li CP; Li R
    World J Radiol; 2023 Nov; 15(11):324-337. PubMed ID: 38058605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study.
    Khan R; Massel D; Stirrat J; Scholl D; Wisenberg G; Thompson T; Drangova M; White JA
    Int J Cardiovasc Imaging; 2013 Feb; 29(2):395-404. PubMed ID: 22875171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between circulating galectin-3, extracellular matrix fibrosis and outcomes in dilated cardiomyopathy.
    Rubiś P; Holcman K; Dziewięcka E; Wiśniowska-Śmiałek S; Karabinowska A; Szymonowicz M; Khachatryan L; Wypasek E; Garlitski A; Gackowski A; Podolec P
    Adv Clin Exp Med; 2021 Mar; 30(3):245-253. PubMed ID: 33754503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy.
    Buss SJ; Breuninger K; Lehrke S; Voss A; Galuschky C; Lossnitzer D; Andre F; Ehlermann P; Franke J; Taeger T; Frankenstein L; Steen H; Meder B; Giannitsis E; Katus HA; Korosoglou G
    Eur Heart J Cardiovasc Imaging; 2015 Mar; 16(3):307-15. PubMed ID: 25246506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T1 Mapping and Extracellular Volume Fraction in Dilated Cardiomyopathy: A Prognosis Study.
    Li S; Zhou D; Sirajuddin A; He J; Xu J; Zhuang B; Huang J; Yin G; Fan X; Wu W; Sun X; Zhao S; Arai AE; Lu M
    JACC Cardiovasc Imaging; 2022 Apr; 15(4):578-590. PubMed ID: 34538631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Elevated Plasma Galectin-3 for Renal Adverse Events in Dialysis Patients: A Systematic Review and Meta-Analysis.
    Lu H; Shen J; Sun J; Sun J
    Altern Ther Health Med; 2023 Nov; 29(8):86-91. PubMed ID: 37652423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy.
    Assomull RG; Prasad SK; Lyne J; Smith G; Burman ED; Khan M; Sheppard MN; Poole-Wilson PA; Pennell DJ
    J Am Coll Cardiol; 2006 Nov; 48(10):1977-85. PubMed ID: 17112987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.